Sleeveless Top New Journey by VIDA VIDA Free Shipping Very Cheap New Arrival Cheap Online Low Shipping Fee Cheap Price kuni77Pe3

SKU911201142438540210335
Sleeveless Top - New Journey by VIDA VIDA Free Shipping Very Cheap New Arrival Cheap Online Low Shipping Fee Cheap Price kuni77Pe3
Sleeveless Top - New Journey by VIDA VIDA

Stanford University

Top

Research

close

Publications

close

Library Archives

close

; European Respiratory Society and European Society of Clinical Microbiology and Infectious Diseases (September 2011)

; NICE Clinical Guideline (December 2014)

; Physician judgement is a crucial adjunct to pneumonia severity scores in low-risk patients. Eur Respir J. 2011 Sep38(3):643-8. doi: 10.1183/09031936.00172910. Epub 2011 Mar 15.

; Risk stratification of Community acquired pneumonia, 2006.

; Is activity against "atypical" pathogens necessary in the treatment protocols for Clin Infect Dis. 2008 Dec 147 Suppl 3:S232-6.

; Mycoplasma pneumonia: Clinical features and management. Lung India. 2010 Apr27(2):75-85. doi: 10.4103/0970-2113.63611.

; Infections caused by Chlamydophila pneumoniae. Adv Clin Exp Med. 2014 Jan-Feb23(1):123-6.

; Atypical pathogens and challenges in community-acquired pneumonia. Am Fam Physician. 2004 Apr 169(7):1699-706.

; Empiric antibiotic coverage of atypical pathogens for community-acquired pneumonia in hospitalized adults. Cochrane Database Syst Rev. 2012 Sep 129:CD004418. doi: 10.1002/14651858.CD004418.pub4.

; Elderly patients with community-acquired pneumonia: optimal treatment strategies. Drugs Aging. 2011 Jul 128(7):519-37. doi: 10.2165/11591980-000000000-00000.

; Role of rifampin-based combination therapy for severe community-acquired Legionella pneumophila pneumonia. Ann Pharmacother. 2011 Jul45(7-8):967-76. doi: 10.1345/aph.1Q074. Epub 2011 Jul 20.

; Clinical Infectious Disease, 2008.

; NICE CKS, August 2012 (UK access only)

; Long-term prognosis in community-acquired pneumonia. Curr Opin Infect Dis. 2013 Apr26(2):151-8. doi: 10.1097/QCO.0b013e32835ebc6d.

; Quinolones versus macrolides in the treatment of legionellosis: a systematic review and meta-analysis. J Antimicrob Chemother. 2014 Sep69(9):2354-60. doi: 10.1093/jac/dku159. Epub 2014 May 14.

Related Information

View all

I'm 38 years old, relatively healthy. This past Tuesday I started feeling unwell and dizzy. My temp is normally in the 97's, it was 99.4. Since then I've had an off/on low grade fever for almost 6...

amanda02808
Join the discussion on the forums
Health Tools

Feeling unwell?

Assess your symptoms online with our free symptom checker.

Start symptom checker
19 January 2020 2624 (v27) Prof Cathy Jackson

Disclaimer: This article is for information only and should not be used for the diagnosis or treatment of medical conditions. Patient Platform Limited has used all reasonable care in compiling the information but make no warranty as to its accuracy. Consult a doctor or other health care professional for diagnosis and treatment of medical conditions. For details see our Figure Shaping Boxer Shorts Black HEMA For Cheap Price View For Sale Cheap Collections Discount Excellent Outlet Very Cheap vhwMFy
.

by Discount Shop Offer Free Shipping Order Camouflageprint briefs The White Briefs Cheap Sale Low Shipping Fee Best Prices Online Buy Cheap Reliable IBYPiNUd
.

NuMedii will collaborate with researchers at Yale School of Medicine and Brigham and Women’s Hospital to develop precision therapies and biomarkers for idiopathic pulmonary fibrosis (IPF).

Under this strategic research collaboration, the company will work with teams of two leading experts in interstitial lung disease: Naftali Kaminski, MD, a professor of internal medicine and chief of pulmonary, critical care and sleep medicine atYale School of Medicine, and; Ivan O. Rosas, MD, a physician at Brigham and Women’s Hospital and associate professor at Harvard Medical School .

The collaboration brings together a large repository of single-cell RNA sequencing data, which integrates information about both the sequence and the quantity of each RNA molecule, from IPF patients and NuMedii’s area of technology called Artificial Intelligence for Drug Discovery (AIDD).

NuMedii’s AIDD technology involves diverse AI methods, ranging from classical machine learning approaches to a new subfield called deep learning, a method in which each step is based on what is “learned” from the previous one.

With AIDD, the company uses hundreds of millions of molecular, pharmacological and clinical data points, which are coupled with NuMedii-developed algorithms (sets of rules that computers use to solve mathematical problems) to find and develop treatment candidates and biomarkers for clinical research in IPF and other disorders.

“The combination of NuMedii’s AIDD technology with this rich data repository will provide unparalleled discovery capabilities to uncover novel mechanisms, cell types, targets and biomarkers that we believe will be instrumental in identifying and developing precision therapies for orphan diseases like IPF,” Gini Deshpande, PhD, CEO at NuMedii, said in a TROUSERS Bermuda shorts Universal Works Top Quality Cheap Price ADPAJkZm
.

Deshpande emphasized the company is “excited” to partner with Kaminski and Rosas to help advance NuMedii’s research in IPF, a condition with “a significant unmet medical need,” he noted.

“Our teams have been at the forefront of analyzing human IPF samples using high throughput technologies for many years,” said Kaminski, who also is a member of NuMedii’s recently created advisory board. He added that the molecular profiling of thousands of cells from patients’ samples “will allow us to understand disease at an unprecedented resolution and should allow us to identify new cell types and biological mechanisms involved in IPF.”

Rosas said the combination of scientific research with NuMedii’s data analytics and drug discovery capabilities may boost “the translation of our research into new precision therapies that will help patients with IPF and the physicians who treat them.”

Common Sense is the nation's leading nonprofit organization dedicated to improving the lives of kids and families by providing the trustworthy information, education, and independent voice they need to thrive in the 21st century.
Headquartered in San Francisco, with offices in Los Angeles, New York, and Washington, D.C.

Follow Common Sense Education

Search Common Sense Education
Subscribe to our newsletters
Privacy policy Terms of service Community guidelines
© Common Sense. All rights reserved.
Common Sense, Common Sense Media, Common Sense Education, and Common Sense Kids Action, associated names, associated trademarks, and logos are trademarks of Common Sense Media, a 501(c)(3) nonprofit organization (FEIN 41-2024986).

Common Sense is the nation's leading independent non-profit organization dedicated to empowering kids to thrive in a world of media and technology.

Families, educators, and policymakers turn to Common Sense for unbiased information and trusted advice to help them learn how to harness the positive power of media and technology for all kids.